slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 225,031-225,060
Pages 10,126
Rows per page 30
Component
225,031-225,060 of 303,780
17
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
18
The slide uses a timeline-based process diagram to illustrate the randomization and treatment arms of the clinical trial.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
19
The slide outlines two distinct treatment arms involving Imdusiran, VTP-300, and Nivolumab.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
20
The slide details a specific licensing deal with Qilu Pharmaceutical.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
21
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
22
The slide uses a three-column layout to explain the scientific basis and therapeutic advantages of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
23
The slide shows two distinct experiments: an in vitro T-cell activation assay and an in vivo tumor reduction study.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
24
The slide outlines a sequential dose-escalation study design.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
25
The slide uses checkmarks to indicate completed milestones.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations Beat · Financials1 hit
26
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Conference presentation Investor relations 1 hit
01
argenx SE | Investor Presentation Deck | 25 slidesargenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
02
argenx SE | Investor Presentation Deck | 25 slidesargenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
03
The slide uses a background image of a sea with a network-like overlay, reinforcing the 'connected' or 'scientific' theme.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
04
argenx SE | Investor Presentation Deck | 25 slidesargenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
The slide highlights the two different delivery methods (IV vs Subcutaneous) for the same underlying treatment.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide uses a hub-and-spoke visual arrangement around a central patient image.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
08
The slide uses a central circular image overlaying four strategic pillars.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
09
The slide uses a 3D-like growth chart to illustrate simultaneous expansion strategies.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
11
The map uses teal dots for general approvals and a purple dot for a specific location (likely US/Canada focus).argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
12
The slide uses a pyramid structure to represent market size, with larger patient populations at the base.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
13
The slide uses a patient-centric approach to humanize clinical trial data and innovation progress.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
14
The slide outlines a clinical trial protocol timeline.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
15
The slide outlines a clinical trial protocol with a 1-3 week screening phase followed by a 30-week treatment period.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
16
The slide uses a split-screen layout to contrast the established MMN proof-of-concept (left) with the future clinical roadmap (right).argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
17
Includes a biological mechanism diagram on the left and a clinical trial design timeline on the right.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
18
The slide uses a hub-and-spoke style network visualization to represent partnerships.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
19
The slide uses a mix of checkmarks for completed items and specific timeframes for future items.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
20
The diagram uses a hub-and-spoke layout with the company logo at the center.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
21
The chart uses a horizontal bar format to represent clinical trial progress for multiple indications under three main programs (VYVGART, ARGX-117, ARGX-119).argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit
22
Clinical trial design schematic showing randomization, screening criteria, and study endpoints.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations 1 hit